Proactive Investors - Run By Investors For Investors

Shire rises on the back of positive results from trial of swelling treatment

Although not generally life threatening, the condition can be painful and debilitating
Swollen leg
The genetic disorder is estimated to affect between one in 10,000 and one in 50,000 people worldwide

Shares in Shire Plc (LON:SHP, NASDAQ:SHPG) rose after it published positive results of a trial of a treatment for swelling under the skin (angioedema).

In London, the shares were up 4.6% at 4,952p as the company said its investigational treatment lanadelumab was shown to reduce the hereditary angioedema (HAE) monthly attack rate by 87% in a Phase 3 26-week pivotal trial.

Data from the trial will form the basis of a biologics licence application (BLA) for evaluation by the US Food and Drug Administration (FDA).

Lanadelumab has already received both Orphan Drug Designation and Breakthrough Therapy Designation from the FDA and Orphan Drug Designation from the European Medicines Agency (EMA), which basically means the drug will be fast-tracked through the regulatory process.

“If approved, lanadelumab may offer patients a long-acting treatment option that significantly reduces HAE attacks when administered subcutaneously [beneath the skin] as infrequently as every four weeks,” said the clinical trial’s investigator, Aleena Banerji, MD, of Massachusetts General Hospital in Boston, Massachusetts.

The condition is not normally life threatening, unless it affects the throat, but can be very painful. The genetic disorder is estimated to affect between one in 10,000 and one in 50,000 people worldwide, and tends to affect the hands, feet, area around the eyes, the lips and tongue and the genitals.

Shire’s lanadelumab was generally well tolerated over the 26-week treatment period. No treatment-related serious adverse events or deaths were reported. The most common adverse event was pain around the area where the injection was made.


Register here to be notified of future SHP Company articles
View full SHP profile View Profile

Shire Plc Timeline

November 01 2016
September 29 2016

Related Articles

cancer cells
February 10 2017
It has already got £7.2mln of the £14.9mln it is looking to raise, which will help fund the development of two promising cancer drug candidates: RXC004 and RXC005
March 01 2017
The new funds will be used to expand the pre-clinical and early-clinical development of the company’s immuno-oncology drug, Clevegen
May 03 2017
The hybrid pharma services and drug development group has hit some key milestones over this year as trial results are eyed.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use